We are the Frontier
U.S.

Huntington's Gene Therapy Gets Faster FDA Review

The FDA will decide on uniQure's AMT-130 by May 1, 2027, after a failed four-year trial.

Updated on Nov. 2, 2026 in Biotech

Frozen cryogenic dewars with faint vapor rising on a steel laboratory bench under soft cool daylight, a quiet research setting.
The FDA said it will decide by May 1, 2027, on uniQure's gene therapy AMT-130 for Huntington's disease, after reversing a earlier stance that called the product a failed one. AI Illustration. Upload story photo >

The FDA has accepted uniQure's application for AMT-130, its gene therapy for Huntington's disease, and will decide on it by May 1, 2027. The application is research-stage in the sense that it is under review and has not been approved for use.

Why it matters

The FDA reversed course after a senior official had called AMT-130 a "failed product" following a four-year trial that did not slow disease progression. The agency is now reviewing the application under its accelerated approval pathway, which allows speedier approval on early evidence while requiring confirmation of benefit in later studies.

The application rests on early- to mid-stage study results from 51 treated patients, set against an external Huntington's disease database rather than a concurrent randomized control group. The four-year trial that failed to slow disease progression is the main counterpoint, and the FDA has not yet resolved how to weigh the two.

The players

uniQure

A Dutch gene therapy developer whose lead programs include AMT-130, its Huntington's disease treatment.

U.S. Food and Drug Administration

The federal agency that regulates drugs and gene therapies in the United States and is reviewing AMT-130 under its accelerated approval pathway.

The details

AMT-130 is a gene therapy, meaning it delivers genetic material into cells to change how they function, and uniQure is a Dutch developer of such treatments. The application compares treated patients with a group of patients from an external Huntington's disease database, a method used when a concurrent control group is not available. The FDA's accelerated approval pathway lets a drug be cleared on early evidence, on the condition that its benefit is confirmed in future studies.

Timeline

  1. The four-year trial in which AMT-130 failed to slow disease progression ended months before November 2, 2026.

  2. The FDA accepted uniQure's AMT-130 application on November 2, 2026.

  3. uniQure plans to begin US patient screening for a follow-up trial by year-end 2026.

  4. The FDA's decision deadline on AMT-130 is May 1, 2027.

The Tech Race

Gene therapies for neurodegenerative diseases are being evaluated through regulatory pathways designed for early evidence, and AMT-130 is among the first such cases to be reviewed after a failed trial. The outcome will indicate how the FDA weighs external comparison groups against a negative randomized result.

If approved, AMT-130 would be the first gene therapy available to Huntington's disease patients, though no approval has been granted and no timeline for availability has been announced. uniQure plans US patient screening for a 200-patient follow-up trial by year-end 2026, in which two-thirds of participants would receive the gene therapy and the rest standard care.

The takeaway

Watch whether the FDA convenes an outside expert panel and whether its May 1, 2027 decision on AMT-130 is met. The result will show how the agency treats an external-database comparison after a failed four-year trial.

What happens next

The FDA is considering holding a meeting of outside experts to discuss the application, and its decision on AMT-130 is due by May 1, 2027.

Further reading

For context on how the agency handles these cases, see Biotech coverage on the United States regulatory landscape.